A Real-World Data Retrospective Cohort Study of HER2-positive, Early-Stage Breast Cancer in Patients 70 Years of Age or Older: Natural History, Treatment Patterns, and Outcomes.

[1]  E. Winer,et al.  Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Amy M. Sitapati,et al.  Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  C. Perou,et al.  Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[5]  P. Fasching,et al.  Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer , 2019, The New England journal of medicine.

[6]  H. Wildiers,et al.  Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. , 2018, The Lancet. Oncology.

[7]  Marion Procter,et al.  Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast Cancer , 2017, The New England journal of medicine.

[8]  M. Ellis,et al.  Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. , 2015, The New England journal of medicine.

[9]  J. Baselga,et al.  Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. , 2014, The Lancet. Oncology.

[10]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Schneeweiss,et al.  Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  A. Goldhirsch,et al.  Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials. , 2013, Cancer treatment reviews.

[13]  H. Wildiers,et al.  Triple-negative breast cancer in the older population. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  H. Rugo,et al.  Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study , 2012, Breast Cancer Research and Treatment.

[15]  N. Taira,et al.  Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)]. , 2011, Japanese journal of clinical oncology.

[16]  C. Geyer,et al.  Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[18]  J. Goodwin,et al.  Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[20]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[21]  Giulia Bianchi,et al.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.